CapitolRadar tracks every publicly disclosed TECX trade by US congress members and corporate insiders: 0 disclosed trades (0 buys, 0 sells) by 0 tracked traders. Updated daily from official filings.
Want a ping when Congress buys TECX? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Tectonic Therapeutic, Inc. (TECX) — Healthcare · Biotechnology, market cap about $0.4B.
Cluster watch: 5 distinct tracked traders disclosed buying TECX in the last 45 days: Schwabish Marc (officer: Chief Business Officer), McNamara Peter (officer: Chief Scientific Officer), Lochner Daniel (officer: Chief Financial Officer), Ruddy Marcella K. (officer: Chief Medical Officer), REICIN ALISE (director, officer: Chief Executive Officer).
CapitolRadar signal history
RISK ALERT 2026-09-17
CapitolRadar's automatic risk rules flagged the TECX pick because the price gave back more than 10% from its high since the pick ($30.62). Current price: $27.32. This is a rule-based checkpoint, not a prediction — review the pick and decide for yourself.
NEW PICK 2026-09-08
TECX CEO and director Alise Reicin disclosed buying 69,250 shares for about $2.07 million. The panel found the large purchase notable because four other TECX executives also bought shares within 45 days. The biggest caveat is that Reicin has no verified trading history on file, so this insider signal remains unproven.
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass…
Frequently asked questions
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.